Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )
|
|
- Annis McDaniel
- 5 years ago
- Views:
Transcription
1 Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November
2 Summary Toujeo uses the same insulin glargine molecule as Lantus, but is a higherstrength formulation (300 units/ml), than the existing insulin glargine product on the market (Lantus, 100 units/ml). Toujeo is intended to have a flatter and more prolonged pharmacodynamic profile than Lantus and offers the benefit of a smaller volume of subcutaneous injection. Toujeo is licensed for the treatment of diabetes mellitus in adults. Toujeo was shown to be non-inferior to Lantus in reducing HBA1c in both T1DM and T2DM. The incidence of nocturnal severe and/or confirmed hypoglycaemia was a significantly lower with Toujeo in T2DM, but showed no difference in T1DM. The overall safety profile of Toujeo was comparable to the well-established safety profile of Lantus. No new or unexpected safety signals were detected. Abasaglar is the first biosimilar insulin approved in the EU. It has an identical amino acid sequence to that of the active ingredient in the reference product Lantus. The licensed indication (treatment of diabetes mellitus in adults, adolescents and children aged two years and above), dosing regimen, pharmaceutical form, and strength of Abasaglar are identical to those of Lantus. In extensive comparability exercises all major physicochemical characteristics and biological activities of Abasaglar were comparable to those of Lantus. Abasaglar was shown to be non-inferior to Lantus in reducing HBA1c in both T1DM and T2DM. The overall safety profile of Abasaglar was comparable to Lantus and was in line with the documented safety profile of the reference product. No new or unexpected safety signals were detected. NICE NG17 (2015) recommends multiple daily insulin injection basal-bolus regimens, rather than twice-daily mixed insulin regimens as the insulin injection regimen of choice in T1DM. Twice daily insulin detemir should be offered as basal insulin therapy. If a twice-daily insulin regimen is not acceptable, once-daily insulin glargine or detemir should be considered. Once-daily insulin glargine should also be considered if insulin detemir is not tolerated. NICE CG87 (2009) recommends NPH insulin as the preferred insulin therapy in T2DM, although long-acting insulin analogues may have a role in treating specific patients. In the NETAG area more is spent on drugs for diabetes than any other BNF section, with 45.1 million spent between April 2014 and March A total of 425,392 insulin items were prescribed at a cost of around 19.1 million. Of these, insulin glargine accounted for 83,361 items (20%) at a cost of around 4.4 million. The per unit acquisition cost of Toujeo is lower than Lantus. However, Toujeo and Lantus are not bioequivalent and therefore are not interchangeable. On a unit to unit basis, Toujeo has a lower glucose lowering effect than Lantus, and therefore higher doses of Toujeo (10-18%) may be required to achieve similar levels of glucose control. The per unit acquisition cost of Abasaglar represents a discount of approximately 15% on the corresponding list price of Lantus. Although the dosing regimen, pharmaceutical form, and strength of Abasaglar are identical to those of Lantus, some patients may still need an adjustment in dose. Northern Treatment Advisory Group, November
3 Introduction and background Diabetes mellitus (DM) is a chronic metabolic disorder, caused by defects in insulin secretion, insulin action, or both. In type 1 diabetes mellitus (T1DM) the pancreas is no longer able to produce sufficient insulin, due to destruction of the pancreatic islet cells most commonly by an autoimmune process. As a consequence, people with T1DM are prone to developing hyperglycaemia, and require life-long insulin replacement. Until recently, the two most commonly used treatment regimens for T1DM were twice daily injections of a meal-time and basal insulin together, or a basalbolus regimen, with meal-time insulin taken prior to main meals, with once or twice daily dosing of basal insulin. In type 2 diabetes mellitus (T2DM) a combination of impaired insulin secretion and insulin resistance results in elevated blood glucose levels. Treatment initially involves lifestyle changes, with oral antihyperglycaemic drugs added as necessary to maintain adequate blood glucose control. Due to progressive islet cells failure, many patients with T2DM will eventually require insulin replacement and will commence once daily insulin to supplement oral therapy before moving to more involved regimes such as twice daily insulin mixtures or basal bolus insulin therapy. 1-5 Insulin glargine (Lantus, Sanofi) is a long-acting recombinant analogue of human insulin. It was approved in 2006 for the treatment of DM in adults, adolescents and children aged two years and above. The efficacy and safety of insulin glargine are well established through extensive clinical and observational studies involving over 200,000 patients. 1,6 Toujeo (Sanofi) uses the same insulin glargine molecule as Lantus, but is a higher-strength formulation (300 units/ml), than the existing insulin glargine product on the market (Lantus, 100 units/ml). Toujeo is intended to have a flatter and more prolonged pharmacodynamic profile than Lantus and offers the benefit of a smaller volume of subcutaneous injection. Toujeo is licensed for the treatment of DM in adults. In T1DM, Toujeo must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements. In patients with T2DM mellitus, it can also be given together with other anti-hyperglycaemic medicinal products. 1,7 Abasaglar is the first biosimilar insulin approved in the European Union. This longacting insulin analogue has an identical amino acid sequence to that of the active ingredient in the reference product Lantus. Abasaglar differs from Lantus with respect to excipients used, but the final quantitative formulation is the same. The licensed indication, dosing regimen, pharmaceutical form, and strength of Abasaglar are identical to those of the reference product Lantus. 2,8 Both products were launched in the UK in August The patent for Lantus expired in the EU in May This report will review the evidence for the use of high-strength insulin glargine (Toujeo ) and biosimilar insulin glargine (Abasaglar ) in the treatment of diabetes. Northern Treatment Advisory Group, November
4 Guidance and related advice NICE guideline (NG17, 2015) for the management of T1DM recommends multiple daily insulin injection basal-bolus regimens, rather than twice-daily mixed insulin regimens as the insulin injection regimen of choice for all adults with T1DM. 9 Patients should be provided with guidance on using multiple daily injection basal bolus insulin regimens. Newly diagnosed patients should not be offered non basal bolus insulin regimens. Twice daily insulin detemir should be offered as basal insulin therapy. As an alternative, consider using an existing insulin regimen that is achieving agreed glucose targets, or once-daily glargine or detemir, if twice daily insulin regimen is not acceptable to the patient. Once daily insulin glargine should be considered if insulin detemir is not tolerated. Other basal insulin regimens should only be considered if the above do not deliver agreed targets. The choice of alternative insulin regimen should take into account patient preferences and acquisition cost. The current NICE guideline on T2DM (CG87, 2009) recommends insulin therapy when glycaemic control becomes or remains inadequate with other measures. 10 Human NPH insulin (isophane) once or twice-daily is the preferred option for most patients. The guideline recommends that the long-acting insulin analogues, insulin glargine and insulin detemir can be considered in some people, in certain circumstances (e.g. patients with significant hypoglycaemia, those requiring assistance to administer, or a need to reduce the number of daily injections). NICE Evidence summary for Toujeo in T1DM was published in October The publication date for the evidence summary in T2DM is to be confirmed. NICE will not review Abasaglar separately as part of their technology appraisal programme. A NICE Evidence Summary for Abasaglar is due to be published in November The SMC has accepted Toujeo for restricted use within NHS Scotland following an abbreviated submission. 12 Its use should be targeted on patients with T1DM who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In T2DM it should be restricted to those who suffer from recurrent episodes of hypoglycaemia or require assistance with their insulin injections. The SMC will not review Abasaglar following their recent update to the SMC policy for biosimilar medicines. An AWMSG appraisal of Abasaglar is currently in process. No review of Toujeo is currently on the AWMSG workplan. Clinical evidence Toujeo Insulin glargine 300 units/ml 1,13-18 The clinical efficacy of Toujeo (insulin glargine 300 units/ml) given once-daily was compared to that of once-daily Lantus (insulin glargine 100 units/ml) in four openlabel, randomised, active-control, parallel group studies of up to 26 weeks duration in patients with T1DM (EDITION 4), and patients with T2DM (EDITION 1, 2 and 3). Each study comprised of a six-month main study period followed by a six-month comparative safety extension period. Adult patients aged 18 years of age with a screening HbA1c of 7.0% to 10.0% for insulin pre-treated patients, and 7.0% to Northern Treatment Advisory Group, November
5 11.0% in insulin naïve patients were eligible for the studies. Exclusion criteria were as unrestrictive as possible to reflect the general population with diabetes mellitus. All four studies were designed to show non-inferiority of Toujeo versus Lantus based on the primary endpoint of change in HbA 1c from baseline to month six, with a noninferiority margin of 0.4% HbA1c, and if met 0.3%. The primary efficacy analyses were based on a modified intent-to treat (mitt) population defined as all randomized patients who received at least one dose of Toujeo or Lantus study medication, and who had both a baseline assessment and at least one post-baseline assessment of any primary or secondary efficacy endpoint. The key secondary efficacy endpoints was the proportion of patients experiencing at least one severe and/or confirmed nocturnal hypoglycaemia ( 3.9 mmol/l) from week nine to month six. Other secondary endpoints included fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG), change in body weight, and change in basal insulin dose. Patients with T1DM 1,14 In EDITION 4, patients with T1DM were randomised to once-daily Toujeo or Lantus in the morning or evening while continuing to use their mealtime insulin. Participants had to have been on basal insulin in combination with mealtime insulin for at least one year. The starting insulin glargine dose was based on total basal insulin dose and fasting SMPG at baseline. The mean age was 47.3 years, mean duration of diabetes 21.0 years, and BMI At week 26, the change in HbA1c was comparable in the two treatment-groups. The upper bound of the 95% CI (0.19%) was within the predefined non-inferiority margin of 0.40%, and the more stringent criteria of 0.3% (Table 1). Similar reductions were observed for FPG and SMPG. No clinically meaningful differences in glycaemic control were observed when morning and evening injection time was compared, including overlapping 8-point SMPG profiles. The percentage of patients with severe and/or confirmed nocturnal hypoglycaemia was similar between groups. There were no clinically important differences in body weight between treatment groups. Table 1: Phase 3 clinical trial of Toujeo in adult patients with type 1 diabetes mellitus. EDITION 4 Population T1DM previously treated with basal insulin Treatment group Toujeo Lantus Treatment in combination with Meal-time insulin analogue Number of subjects treated (mitt) HbA1c Baseline mean Adjusted Mean change from baseline Adjusted Mean difference 0.04 [95% CI] [ to 0.18] Severe and/or confirmed nocturnal hypoglycaemia Number (%) 162 (59.3%) 153 (56.05) Relative risk vs. Lantus 1.06 [95% CI] [0.92 to 1.23] p-value Northern Treatment Advisory Group, November n/a
6 Patients with T2DM 1,13,15-18 In EDITION 1, patients with T2DM were randomised to once-daily Toujeo or Lantus in the evening while continuing to use their mealtime insulin with or without metformin. Participants had to have been on basal insulin ( 42 units/day) in combination with a mealtime for at least one year. The starting insulin glargine dose was based on total basal insulin dose and fasting SMPG at baseline. The mean age was 60 years, mean duration of diabetes 15.8 years, and BMI In EDITION 2 and 3, patients with T2DM were randomised to once-daily Toujeo or Lantus as part of a combination regimen with non-insulin anti-hyperglycaemic drugs. At the time of randomisation patients in EDITION 2 had to have been on basal insulin for at least six months. The mean age of patients in EDITION 2 was 58.2 years, mean duration of diabetes 12.6 years, and BMI Patients in EDITION 3 were insulin naïve, and had mean age was 57.7 years, mean duration of diabetes 9.8 years, and BMI At week 26 in all three studies, treatment with Toujeo resulted in a mean reduction in HbA1c that met the predefined inferiority margin of 0.4% and 0.3%, compared to Lantus (table 2.). Similar reductions were observed for FPG and SMPG profiles. Toujeo was associated with fewer participants experiencing one or more confirmed and/or severe nocturnal hypoglycaemic events compared to Lantus. There were no clinically important differences in body weight between treatment groups. However, patients receiving Toujeo used more basal insulin than patients treated with Lantus (115, 12% and 15% for EDITION 1, 2 and 3, respectively). Table 2: Phase 3 clinical trials of Toujeo in adult patients type 2 diabetes mellitus. Population EDITION 1 EDITION 2 EDITION 3 T2DM previously treated with basal insulin T2DM previously treated with basal insulin T2DM previously insulin naïve Treatment group Toujeo Lantus Toujeo Lantus Toujeo Lantus Treatment in combination with Number of subjects treated (mitt) HbA1c Meal-time insulin analogue +/- metformin Non-insulin antihyperglycaemic drugs Non-insulin antihyperglycaemic drugs Baseline mean Adjusted Mean change from baseline Adjusted Mean difference [95% CI] [-0.14 to 0.08] [-0.17 to 0.10] [-0.09 to 0.17] Severe and/or confirmed nocturnal hypoglycaemia Number (%) 146 (36.1%) 184 (46.0%) 87 (21.6%) 113 (27.9%) 67 (15.5%) 75 (17.4%) Relative risk vs. Lantus [95% CI] [0.67 to 0.93] [0.61 to 0.99] [0.66 to 1.20] p-value Northern Treatment Advisory Group, November
7 Abasaglar Insulin glargine biosimilar 100 units/ml 2,19,20 To gain approval in the EU, biosimilar medicines must demonstrate that they are as safe and as effective as the reference medicine, and have the same quality characteristics. The EU regulatory process demands an extensive comparability exercise is performed through a stepwise process that begins with structural, physicochemical and biological analysis, non-clinical, then pharmacokinetic (PK) and pharmacodynamic studies (PD), followed by clinical safety and efficacy trials. In the extensive comparability exercise it was shown that the PK and PD profiles, the relative bioavailability and the duration of action of Abasaglar are comparable to those of Lantus. The clinical efficacy of Abasaglar (biosimilar insulin glargine 100 units/ml) given oncedaily was compared to that of once-daily Lantus (insulin glargine 100 units/ml) in two similarly designed randomised, active-control, parallel group studies. ELEMENT 1 was a 52 week study (24-week treatment period and 28-week extension) in patients with T1DM, and ELEMENT 2 was a 24-week study in patients with T2DM. Adult patients aged 18 years of age with a screening HbA1c of 11.0% for insulin pretreated patients and 7.0% to 11.0% in insulin naïve patients were eligible for the studies. Exclusion criteria were largely unrestrictive and reflect the general population with diabetes mellitus. Both studies were designed to show non-inferiority of Abasaglar versus Lantus based on the primary endpoint of change in HbA1c from baseline to 24 weeks, with a non-inferiority margin of 0.4% HbA1c, and if met 0.3%. The primary efficacy analyses were based on full intent-to treat (ITT). Secondary efficacy endpoints included fasting blood glucose (FBG), self-monitored blood glucose (SMBG), change in body weight, and change in basal insulin dose. Patients with T1DM 2,19 In ELEMENT 1, patients who had T1DM for at least one year were randomised to once-daily Abasaglar or Lantus started on the same dose at the same time of day as their basal insulin. At randomization, all patients mealtime insulin was replaced with insulin lispro at doses equivalent to their mealtime insulin. Insulin dose adjustments were carried out in both treatment groups to help patients achieve glycaemic targets. The mean age was 41.2 years, mean duration of diabetes 16.4 years, and BMI Both treatment groups achieved similar decreases in mean HbA1c values from baseline to 24 weeks and 52 weeks. Abasaglar was found to be non-inferior to Lantus at the predefined inferiority margin of 0.4%, and the more stringent criteria of 0.3% (table 3.). For 7-point SMBG, patients in the Abasaglar arm had statistically significantly lower mean BG values at bedtime and 3 am compared with the Lantus arm; however, the mean difference between treatment arms was small and unlikely to result in clinically meaningful differences. There were no significant differences in other efficacy measures, including FBG, insulin dose, and body weight at 24 and 52 weeks. Northern Treatment Advisory Group, November
8 Table 3: Phase 3 clinical trial of Abasaglar in adult patients with type 1 diabetes mellitus. Population ELEMENT 1 24 weeks 52 weeks T1DM previously treated with basal insulin T1DM previously treated with basal insulin Treatment group Abasaglar Lantus Abasaglar Lantus Treatment in combination with Number of subjects treated (ITT) HbA1c Meal-time insulin analogue Meal-time insulin analogue Baseline mean NR NR Adjusted Mean change from baseline Adjusted Mean difference [95% CI] [ to 0.22] [ to 0.14] NR= Not reported Patients with T2DM 2,20 ELEMENT 2 enrolled patients with T2DM who were insulin naïve and had been treated with two or more oral antihyperglycaemic drugs at stable doses for 12 weeks. The starting dose for all insulin-naïve patients was 10 units/day. Patients entering the study on Lantus were randomized to either Abasaglar or Lantus at a dose equivalent to their pre-study Lantus dose. Insulin dose adjustments were carried out in both treatment groups to help patients achieve glycaemic targets. The mean age was 58.9 years, mean duration of diabetes 11.4 years, and BMI At week 24, treatment with Abasaglar resulted in a mean reduction in HbA1c that met the predefined inferiority margin of 0.4% and 0.3%, compared to Lantus (table 4.). There were no clinically significant treatment differences in any secondary efficacy measures, including FBG, insulin dose, and body weight at 24 weeks. Table 4: Phase 3 clinical trial of Abasaglar in adult patients with type 2 diabetes mellitus. Population ELEMENT 2 T2DM previously treated with basal insulin Treatment group Abasaglar Lantus Treatment in combination with 2 oral antihyperglycaemic drugs Number of subjects treated (ITT) HbA1c Baseline mean Adjusted Mean change from baseline Adjusted Mean difference 0.05 [95% CI] [-0.07 to 0.17] Northern Treatment Advisory Group, November
9 Safety Toujeo Insulin glargine 300 units/ml 1,13-18 Data supporting the safety of Toujeo are based on the results from the EDITION 4 study plus an exploratory phase 2 study (PDY12777) in patients with T1DM, and the EDITION 1, 2 and 3 studies in patients with T2DM. During the main 24 week ontreatment period, the overall number and pattern of treatment-emergent adverse events (TEAEs) were comparable between Toujeo and Lantus treated patients. TEAEs were reported in 62.8% and 58.9% of patients, respectively in T1DM studies, and in 57.3% and 53.7% of patients, respectively in T2DM studies. In both treatment groups the most commonly reported TEAEs were infections and infestations, with nasopharyngitis and upper respiratory tract infection the most common in both T1DM and T2DM (Table 5.). Overall, serious TEAEs were reported by 5.4% of the patients in both the Abasaglar and Lantus groups, and by a comparable number of patients in the T1DM (5.9% vs.7.2%, respectively) and T2DM studies (5.2% vs. 5.0%, respectively), with no single event driving the results. The most common serious TEAE in the T1DM studies was hypoglycaemia (3.0% vs. 3.9%, respectively; T2DM: <0.1% vs. 0.2%, respectively) and the most common in the T2DM studies was coronary artery disease (0.2% vs. <0.1%, respectively); T1DM: one event, no events, respectively). Table 5. Summary of TEAEs in 3% of all pooled Abasaglar and Lantus patients (EDITION 1, 2, 3, 4 and PDY12777). Preferred Term N, (%) Abasaglar (n=304) T1DM T2DM All studies Lantus (n=304) Abasaglar (n=1,242) Lantus (n=1,246) Abasaglar (n=1,546) Lantus (n=1,550) Any TEAE 191 (62.8%) 179 (58.9%) 712 (57.3%) 669 (53.7%) 903 (58.4%) 848 (54.7%) Nasopharyngitis 39 (12.8%) 33 (10.9%) 88 (7.1%) 72 (5.8%) 127 (8.2%) 105 (6.8%) URTI 29 (9.5%) 23 (7.6%) 71 (5.7%) 67 (5.4%) 100 (6.5%) 90 (5.8%) Headache 14 (4.6%) 14 (4.6%) 61 (4.9%) 47 (3.8%) 75 (4.9%) 61 (3.9%) Diarrhoea 7 (2.3%) 6 (2.0%) 47 (3.8%) 38 (3.0%) 54 (3.5%) 44 (2.8%) Nausea 8 (2.6%) 5 (1.6%) 40 (3.2%) 27 (2.2%) 48 (3.1%) 32 (2.1%) Bronchitis 6 (2.0%) 6 (2.0%) 41 (3.3%) 42 (3.4%) 47 (3.0%) 48 (3.1%) There were no clinically important differences in hypoglycaemia between Toujeo and Lantus among T1DM patients. In EDITION 4, the incidence of severe hypoglycaemia at week 26 was lower in the Toujeo group compared with the Lantus group (6.6% vs. 9.5%, respectively). This difference was largely driven by daytime events. However, annualized rates were comparable between two groups (0.24 vs events/person year at any time of day). The incidence of documented symptomatic hypoglycaemia Northern Treatment Advisory Group, November
10 was comparable at 69% and 69.8%, respectively. In all three studies in T2DM, the cumulative incidence of hypoglycaemia was lower in the Toujeo group than in the Lantus group. The incidence of severe hypoglycaemia was 5% vs. 5.7% at 26 weeks in patients receiving Toujeo and Lantus in combination with mealtime insulin. In the two studies where patients received treatment in combination with non-insulin antihyperglycaemic drugs the corresponding figures were1.0% vs. 1.5% and 0.9% vs. 0.9%, respectively. The incidence of documented symptomatic hypoglycaemia ranged from 7.6% to 37.4% in patients receiving Toujeo vs. 13.9% to 41.5%, and the highest risk was again seen in patients receiving treatment in combination with mealtime insulin. There were no differences in the insulin antibody response and in the clinical effects associated with antibody formation in either treatment group. No new or unexpected safety signals were detected with respect to injection site reactions, hypersensitivity reactions and cardiovascular safety. Abasaglar Insulin glargine biosimilar 100 units/ml 2,19,20 The safety profile of Abasaglar has been well characterised in the context of the extensive comparability exercise, in which it appeared comparable to the established and documented safety profile of the reference product, Lantus. The clinical data supporting the safety of Toujeo are based on the results from the ELEMET 1 and 2 studies in which a total of 446 patients were exposed to Abasaglar for at least six months. In addition 52-week safety data from ELEMENT 1 have been reported. Overall, the incidence and pattern of adverse events (AEs) reported with Abasaglar were comparable to those of Lantus, with no statistically significant differences observed between the two groups (table 6.). In both T1DM and T2DM, the most frequently reported AEs were nasopharyngitis, upper respiratory tract infection and diarrhoea (comparative data have not been reported). Table 6. Overall summary of adverse events in ELEMENT 1 and 2. Preferred Term N, (%) Abasaglar (n=268) Any Adverse Event 167 (62%) Serious Adverse Event 20 (8%) T1DM (52 weeks) Lantus (n=267) 166 (62%) 24 (9%) Abasaglar (n=376) 196 (52%) 15 (4%) T2DM (24 weeks) Lantus (n=380) 184 (84%) 18 (5%) AEs possibly related to study drug 17 (6%) 14 (5%) 26 (7%) 23 (6%) Discontinuations due to an AE 2 (1%) 6 (2%) 6 (2%) 11 (3%) Allergic reactions 20 (8%) 11 (4%) 21 (6%) 27 (7%) Injection site reactions (patient questionnaires) 7 (3%) All treatment comparisons p<0.05, with the exception of injection site reactions (patient questionnaires), and events experienced by <4 patients, where treatment comparisons were not performed. 3 (1%) 13 (4%) 11 (3%) Northern Treatment Advisory Group, November
11 During the main 24 week on-treatment period, the total number of hypoglycaemic events was numerically lower with Abasaglar compared to Lantus in both studies, including the number of severe hypoglycaemic events. However, the estimated difference in the 52-week update of ELEMENT was approximately three events per year, which is not considered clinically meaningful. Likewise in ELEMENT 2, the estimated difference at 24 weeks was around one event per year, with no difference in documented symptomatic hypoglycaemia reported. The proportion of patients with detectable anti-insulin antibodies was comparable throughout both studies. There was no evidence that the antibody response had any impact on efficacy and safety outcomes in either treatment group. No new or unexpected safety signals were detected with respect to injection site reactions, hypersensitivity reactions and cardiovascular safety. Risk minimisation strategy for high strength and biosimilar insulin products Several new insulin products have come to market recently, and healthcare professionals and patients need to understand the insulin strength of these products and how to use them correctly to minimise the risk of medication errors such as the wrong insulin dose being administered. The European Medicines Agency is currently consulting on guidance to minimise the risk of medication error. 21 This draft guidance summarises ways to minimise the risk of medication errors with the high strength, fixed combination and biosimilar insulin products already on the market. Dosage and administration Trade name Formulation/strength Indication Posology and administration Toujeo 7 (Sanofi) Insulin glargine 300 units/ml in 1.5 ml prefilled SoloStar pen. These units are exclusive to Toujeo and are not the same as IU or the units used to express the potency of other insulin analogues. Treatment of diabetes mellitus in adults. Injected once daily subcutaneously. The dose and timing should be adjusted according to individual response In T1DM, Toujeo must be combined with short-/rapid acting insulin to cover mealtime insulin requirements. In T2DM, Toujeo can be given in combination with other antihyperglycaemic drugs Abasaglar 8 (Eli Lilly) Insulin glargine 100 units/ml in a 3 ml prefilled KwikPen, or 3 ml cartridge for use in Lilly reusable pen. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analogues. Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Injected once daily subcutaneously. The dose and timing should be adjusted according to individual response. In T2DM, Abasaglar can be given in combination with oral antihyperglycaemic drugs. Northern Treatment Advisory Group, November
12 Cost analysis No published economic analyses on the use of Toujeo or Abasaglar were identified. In the area more is spent on drugs for diabetes than any other BNF section, with 45.1 million spent between April 2014 and March A total of 425,392 insulin items were prescribed at a cost of around 19.1 million. Of these, insulin glargine accounted for 83,361 items (20%) at a cost of around 4.4 million. The comparative cost of all currently available insulin glargine products is shown in table 7. The per unit acquisition cost of Toujeo is lower than Lantus. However, Toujeo and Lantus are not bioequivalent and therefore are not interchangeable. On a unit to unit basis, Toujeo has a lower glucose lowering effect than Lantus, and therefore higher doses of Toujeo (approximately 10-18%) may be required to achieve similar levels of glucose control. The dosing regimen, pharmaceutical form, and strength of the biosimilar Abasaglar are identical to those of the reference product Lantus. However, some patients may still need an adjustment in dose. The per unit acquisition cost of Abasaglar represents a discount of approximately 15% on the corresponding list price of Lantus. Table 7. Comparative cost of insulin glargine products (dm+d and emims, November 2015). Product Toujeo (300 units/ml) Abasaglar (100 units/ml) Lantus (100 units/ml) Cost per pack of 3 x 1.5ml SoloStar prefilled pen. (1,350 units) per pack of 5 x 3ml prefilled KwikPens. (1,500 units) per pack of 5 x 3ml SoloStar prefilled pen. (1,500 units) per pack of 5 x 3ml cartridges for use in reusable Savvio pen. (1,500 units) per pack of 5 x 3mL cartridges for Autopen 24 and ClikSTAR. (1,500 units) Annual cost per patient (20 units daily)* Annual cost per patient (40 units daily)* Annual cost per patient (60 units daily)* for 1 x 10ml vial. (1,000 units) * On a unit to unit basis, Toujeo has a lower glucose lowering effect than Lantus, and therefore higher doses of Toujeo (approximately 10-18%) may be required to achieve similar levels of glucose control. Northern Treatment Advisory Group, November
13 Points to consider Toujeo is a higher-strength formulation (300 units/ml), than the existing insulin glargine product on the market (Lantus, 100 units/ml), Toujeo is intended to have a flatter and more prolonged pharmacodynamic profile than Lantus and offers the benefit of a smaller volume of subcutaneous injection. It is licensed for the treatment of DM in adults. Toujeo was shown to be non-inferior to Lantus in reducing HBA1c in both T1DM and T2DM. The incidence of nocturnal severe and/or confirmed hypoglycaemia was a significantly lower with Toujeo in T2DM, but showed no difference in T1DM. The overall safety profile of Toujeo was comparable to the well-established safety profile of Lantus. No new or unexpected safety signals were detected. Abasaglar is the first biosimilar insulin approved in the EU. The licensed indication (treatment of diabetes mellitus in adults, adolescents and children aged two years and above), dosing regimen, pharmaceutical form, and strength of Abasaglar are identical to those of the reference product Lantus. In extensive comparability exercises all major physicochemical characteristics and biological activities of Abasaglar were comparable to Lantus. Abasaglar was shown to be non-inferior to Lantus in reducing HBA1c in both T1DM and T2DM. In the comparability exercise and clinical studies the overall safety profile of Abasaglar was comparable to Lantus and in line with the documented safety profile of Lantus. No new or unexpected safety signals were detected NICE NG17 (2015) recommends multiple daily insulin injection basal-bolus regimens, rather than twice-daily mixed insulin regimens as the insulin injection regimen of choice in T1DM. Twice daily insulin detemir should be offered as basal insulin therapy. If a twice-daily insulin regimen is not acceptable, once-daily insulin glargine or detemir should be considered. Oncedaily insulin glargine should also be considered if insulin detemir is not tolerated. NICE CG87 (2009) recommends NPH insulin as the preferred insulin therapy in T2DM, although longacting insulin analogues may have a role in treating specific patients. Toujeo represent an additional treatment option for patients that require a long-acting insulin analogue who are not currently able to achieve optimal glycaemic control. Due to a flatter and more prolonged pharmacodynamic profile Toujeo allows patients greater flexibility in the timing of their once-daily injection compared with Lantus. However, switching from Lantus to Toujeo is not straightforward, as the drugs are not bioequivalent and are not directly interchangeable. A switch can be done on a unit-to-unit basis, but higher doses of Toujeo (approximately 10-18%) may be required to achieve similar levels of glucose control. Abasaglar may be considered as an option for new patients requiring insulin glargine in line with NICE guidelines. However, individual Trusts may wish to consider a managed therapeutic switch between products. Abasaglar has been shown to be bioequivalent to Lantus and the efficacy of the two products are comparable. Nevertheless, as with other biosimilar medicines, some patients may still need an adjustment in dose. In the NETAG area more is spent on drugs for diabetes than any other BNF section, with 45.1 million spent between April 2014 and March A total of 425,392 insulin items were prescribed at a cost of around 19.1 million. Of these, insulin glargine accounted for 83,361 items (20%) at a cost of around 4.4 million. The per unit acquisition cost of Toujeo is lower than Lantus. However, Toujeo and Lantus are not bioequivalent and therefore are not interchangeable. On a unit to unit basis, Toujeo has a lower glucose lowering effect than Lantus, and therefore higher doses of Toujeo (10-18%) may be required to achieve similar levels of glucose control. The per unit acquisition cost of Abasaglar represents a discount of approximately 15% on the corresponding list price of Lantus. Although the dosing regimen, pharmaceutical form, and strength of the biosimilar Abasaglar are identical to those of the reference product Lantus, some patients may still need an adjustment in dose. Northern Treatment Advisory Group, November
14 Author s declaration: The author has no relevant interests to declare. References 1. European Medicines Agency. European public assessment report - Toujeo (insulin glargine). February _Public_assessment_report/human/002835/WC pdf 2. European Medicines Agency. European public assessment report - Abasaglar (insulin glargine). June _Public_assessment_report/human/002835/WC pdf. 3. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Diabetes - type 1. Last revised in June National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Diabetes - type 2. Last revised in July Holt et al., (Eds.), International Textbook of Diabetes Mellitus: 4th Edition. United Kingdom: Wiley-Blackwell Publishing Sanofi. Summary Product Characteristics. Lantus 100 units/ml solution for injection in a vial, cartridge and SoloStar pre-filled pen. Date of revision of text: August Sanofi. Summary Product Characteristics. Toujeo 300 units/ml solution for injection in a pre-filled pen. Date of revision of text: July Eli Lilly. Summary Product Characteristics. ABASAGLAR 100 units/ml solution for injection in cartridge & pre-filled pen. Date of revision of text: July National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management (NG 17). August National Institute for Health and Care Excellence. Type 2 diabetes: The management of type 2 diabetes (CG 87). May National Institute for Health and Care Excellence. Evidence Summary-New Medicine [ESNM62]. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo). October Scottish Medicines Consortium. insulin glargine 300 units/ml solution for injection in a pre-filled pen (Toujeo). SMC No. (1078/15). July Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17: Home PD, Bergenstal RM, Bolli GB et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care Riddle MC, Bolli GB, Ziemen M et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37: Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37: Yki-Jarvinen H, Bergenstal RM, Bolli GB et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs Northern Treatment Advisory Group, November
15 (EDITION 2 randomised 12-month trial including 6-month extension). Diabetes Obes Metab Riddle MC, Yki-Jarvinen H, Bolli GB et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION month randomized trial, including 6-month extension. Diabetes Obes Metab 2015;17: Blevins TC, Dahl D, Rosenstock J et al. Efficacy and safety of LY insulin glargine compared with insulin glargine (Lantus(R)) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab 2015;17: Rosenstock J, Hollander P, Bhargava A et al. Similar efficacy and safety of LY insulin glargine and insulin glargine (Lantus(R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015;17: Medicines and Healthcare products Regulatory Agency. Drug Safety Update: High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error. April Northern Treatment Advisory Group, November
New Medicine Assessment
New Medicine Assessment Insulin Glargine 300 units/ml (Toujeo ) Treatment of type 2 diabetes mellitus in adults Recommendation: Amber 0 Insulin glargine 300 units/ml (Toujeo ) is recommended as an option
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationRe-Submission: Published 10 March February 2014
Re-Submission: insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 07 February
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPriorities Advisory Committee
Insulin degludec (Tresiba ) PAC - Insulin degludec (Tresiba ) 2.1 The East of England Priorities Advisory Committee A function of GUIDANCE STATEMENT PAC Recommendations 1. Insulin degludec is NOT recommended
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationManufacturer Proposed indication. Treatment of type 1 diabetes mellitus (T1DM) in adults who require mealtime insulin to control blood glucose levels
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Prescribing Clinical Network Name, brand
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationoriginal article Introduction
original article Diabetes, Obesity and Metabolism 17: 1142 1149, 215. 215 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ORIGINAL ARTICLE Glycaemic control and hypoglycaemia
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationInsulin for Adults with Type 2 Diabetes
rth Central London Joint Formulary Committee Insulin for Adults with Type 2 Diabetes Disclaimer This guideline is registered at rth Central London (NCL) Joint Formulary Committee (JFC) and is intended
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSunderland Diabetes Network - Recommendations for safe prescribing of insulin.
Sunderland Diabetes Network - Recommendations for safe prescribing of insulin. Note: High strength insulins and biosimilar insulins are for specialist initiation only. They should not be initiated in primary
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationSunderland Diabetes Network - Recommendations for safe prescribing of insulin.
Sunderland Diabetes Network - Recommendations for safe prescribing of insulin. Note: High strength insulins and biosimilar insulins are for specialist initiation only. They should not be initiated in primary
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationCommission. Product. Notification 1. Decision. Information issued on. Issued 2 / affected 3 amended on. 01/02/ /02/2018 SmPC
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification 1 Decision Information issued on Issued 2 / affected
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationHEALTH PROFESSIONAL v SANOFI
CASE AUTH/3062/8/18 HEALTH PROFESSIONAL v SANOFI Toujeo leaflet A consultant physician complained about a six-page A5 gate-folded leavepiece produced by Sanofi. The leavepiece related to Toujeo (insulin
More informationInvestigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD
STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2
More informationCONSULTANT PHYSICIAN v SANOFI
CASE AUTH/2477/2/12 CONSULTANT PHYSICIAN v SANOFI Conduct of representative A consultant physician alleged that at a hospital diabetes meeting a Sanofi representative had been unprofessional in that she
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Bulletin Glucagon-like peptide 1 (GLP-1) receptor agonist review
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2017 Review February 2020 Bulletin 245 - Glucagon-like peptide 1 (GLP-1) receptor agonist review JPC Recommendations:- Place in therapy
More informationSponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationThe BASAGLAR ELEMENT 2 clinical study
insulin glargine injection 100 Units/mL The BASAGLAR ELEMENT 2 clinical study Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationTo assess the safety and tolerability in each treatment group.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationInitiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital
Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTemporary interruption in supply of APIDRA (insulin glulisine) - OPTISET and SOLOSTAR prefilled pens and CLIKSTAR reusable cartridges.
September 2011 Dear Health Care Professional, Temporary interruption in supply of APIDRA (insulin glulisine) - OPTISET and SOLOSTAR prefilled pens and CLIKSTAR reusable cartridges. We would like to inform
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationSHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS
SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS INDICATION Fiasp is indicated for the treatment of diabetes mellitus in adults. Special Note: DMAG has approved
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationhypoglycaemia unawareness keystone 18 July 2014
hypoglycaemia unawareness keystone 18 July 2014 Hypoglycaemia unawareness: ( Impaired awareness of hypoglycaemia ) Philip Home Newcastle University Philip Home Duality of interest Manufacturers of glucose-lowering
More informationInsulin Management. By Susan Henry Diabetes Specialist Nurse
Insulin Management By Susan Henry Diabetes Specialist Nurse The Discovery of Insulin - 1921 - Banting & Best University Of Toronto Discovered hormone insulin in pancreatic extract of dog - Marjorie the
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationWhen and how to start insulin therapy in type 2 diabetes
When and how to start insulin therapy in type 2 diabetes Anne Kilvert MD, FRCP Most patients with type 2 diabetes will eventually require insulin due to the progressive decline in betacell function. Dr
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationSponsor: Sanofi. According to template: QSD VERSION N 5.0 (04-APR-2016) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationPRESCRIBING INCENTIVE SCHEME 2018/19
PRESCRIBING INCENTIVE SCHEME 2018/19 Summary Harrogate and Rural District CCG is continuing to offer a prescribing incentive scheme to all its member NHS GP practices as encouragement and reward to improve
More informationSanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018
Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018 Background: For people with diabetes the early months of treatment with long-acting insulin are important for
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationNew Drug Evaluation: Insulin degludec, subcutaneous injection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationLegal Status Indication Treatment of Type 1 and Type 2 diabetes
New Medicine Report (Adopted by the CCG until review and further notice) Document Status Recombinant human insulin analogues Following Suffolk D&TC Meeting Traffic Light Decision Green Date of Last Revision
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSCIENTIFIC DISCUSSION
London, 5 October 2005 Product name: NovoMix Procedure No. EMEA/H/C/308/X/18 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin 250mg for injection or infusion (Angiox ) (156/05) Nycomed UK Ltd No. 4 February, 2005 The Scottish Medicines Consortium has completed its assessment of the above
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationOpinion 2 April TRESIBA 100 U/ml, solution for injection in prefilled pen B/5 pre-filled pens of 3 ml (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 2 April 2014 TRESIBA 100 U/ml, solution for injection in prefilled pen B/5 pre-filled pens of 3 ml (CIP: 34 009 268
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationDraft Minutes. 15 th September 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Draft Minutes 15 th September 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Present: Elizabeth Adcock (EA) Medicines Information Pharmacist, PAHT Jennifer Bartlett (JB) Senior Medicines Management Pharmacist
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationGuideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus
1 2 3 29 January 2018 CPMP/EWP/1080/00 Rev. 2 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on clinical investigation of medicinal products in the treatment or prevention Draft
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Final scope Appraisal objective To review
More information